TG Therapeutics (TGTX) announced the completion of enrollment in a Phase 3 trial evaluating subcutaneous Briumvi, the company’s anti-CD20 monoclonal antibody, in people with relapsing forms of multiple sclerosis. Briumvi is currently approved in the United States and several ex-US territories as a one-hour intravenous infusion administered twice a year, following the starting dose, in adults with RMS.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TGTX:
- TG Therapeutics Files Procedural 8-K on Financial Obligation
- TG Therapeutics secures additional $500M in non-dilutive capital
- TG Therapeutics board expands share repurchase program to $300M
- TG Therapeutics announces publication of data from studies on Briumvi
- TG Therapeutics Earnings Call Highlights BRIUMVI Surge